Asset Publisher

mp-494

print Print Back Back

Chromoendoscopy as an Adjunct to Colonoscopy

Policy Number: MP-494

Latest Review Date: November 2023

Category: Radiology                                                          

POLICY:

Chromoendoscopy is considered investigational as an adjunct to diagnostic or surveillance colonoscopy.

Virtual chromoendoscopy is considered investigational as an adjunct to diagnostic or surveillance colonoscopy.

DESCRIPTION OF PROCEDURE OR SERVICE:

Chromoendoscopy refers to the application of dyes or stains during endoscopy to enhance tissue differentiation or characterization. When used with colonoscopy, the intent is to increase the sensitivity of the procedure by facilitating the identification of mucosal abnormalities. There are two types of chromoendoscopy: one involves actual spraying of dyes or stains through the working channel of an endoscope; the other, known as virtual chromoendoscopy uses a computer algorithm to simulate different colors of light that results from dye or stain spraying.

Colonoscopy

Colonoscopy, a procedure during which colonic and rectal polyps can be identified and removed, is considered the criterion standard test for colorectal cancer (CC) screening and diagnosis of colorectal disease. However, colonoscopy is an imperfect procedure. A systematic review and meta-analysis by Zhao et al (2019) pooled findings from more than 15,000 tandem (i.e., back-to-back)colonoscopies in 43 publications and found a miss rate of 26% for adenomas, 9% for advanced adenomas, and 27% for serrated polyps. Miss rates were higher for proximal advanced adenomas (14%), serrated polyps (27%), flat adenomas (34%), and in patients at high risk for CC (33%).

Adjunctive Procedures

Several adjunct endoscopic techniques, including chromoendoscopy, could enhance the sensitivity of colonoscopy. Chromoendoscopy, also known as chromoscopy and chromocolonoscopy, refers to the application of topical stains or dyes during endoscopy to enhance tissue differentiation or characterization and facilitate identification of mucosal abnormalities. Chromoendoscopy may be particularly useful for detecting flat or depressed lesions. A standard colonoscopy uses white light to view the colon. In chromoendoscopy, stains are applied, resulting in color highlighting of areas of surface morphology of epithelial tissue. The dyes or stains are applied via a spray catheter that is inserted down the working channel of the endoscope. Chromoendoscopy can be used in the whole colon (pancolonic chromoendoscopy) on an untargeted basis or can be directed to a specific lesion or lesions (targeted chromoendoscopy). Chromoendoscopy differs from endoscopic tattooing in that the former uses transient stains, whereas tattooing involves the use of a long-lasting pigment for future localization of lesions.

Stains and dyes used in chromoendoscopy can be placed in the following categories:

  • Absorptive these stains are preferentially absorbed by certain types of epithelial cells.
  • Contrast these stains seep through mucosal crevices and highlight surface topography.
  • Reactive these stains undergo chemical reactions when in contact with specific cellular constituents which results in a color change.

Indigo carmine, a contrast stain, is one of the most commonly used stains with colonoscopy to enhance the detection of colorectal neoplasms. Several absorptive stains are also used with colonoscopy. Methylene blue is widely used; it stains the normal absorptive epithelium of the small intestine and colon, and has been used to detect colonic neoplasia and to aid in the detection of intraepithelial neoplasia in individuals with chronic ulcerative colitis. In addition, crystal violet (also known as gentian violet), stains cell nuclei and has been applied in the colon to enhance visualization of pit patterns (i.e. superficial mucosal detail). Reactive stains are primarily used to identify gastric abnormalities and are not used with colonoscopy.

Potential applications of chromoendoscopy as an adjunct to standard colonoscopy include:

  • Diagnosis of colorectal neoplasia in symptomatic patients at increased risk of colorectal cancer due to a family history of colorectal cancer, a personal history of adenomas, etc.
  • Identification of mucosal abnormalities for targeted biopsy as an alternative to multiple random biopsies in patients with inflammatory bowel disease (IBD)
  • Screening the general population for colorectal cancer

The equipment used in regular chromoendoscopy is widely available. Several review articles and technology assessments have indicated that, although the techniques are simple, procedures, (e.g., concentration of dye and amount of dye sprayed) is variable and classification of mucosal staining patterns for identifying specific conditions is not standardized.

Virtual chromoendoscopy (also called electronic chromoendoscopy) involves imaging enhancements with endoscopy systems that could potentially be an alternative to dye spraying. One system is the Fujinon Intelligent Color Enhancement (FICE) feature (Fujinon, Inc.). This technology uses post-processing computer algorithms to modify the light reflected from the mucosa from conventional white light to various other wavelengths.

KEY POINTS:

The most recent literature review was updated through September 13, 2023.

Summary of Evidence

Chromoendoscopy

For individuals who have an average risk of colorectal cancer (CC) who receive chromoendoscopy, the evidence includes randomized controlled trials (RCTs) and a meta-analysis of RCTs. Relevant outcomes are overall survival (OS), disease-specific survival (DSS), test validity, and change in disease status. The meta-analysis demonstrated that dye-based chromoendoscopy increased the adenoma detection rate and adenomas per colonoscopy in patients at average or increased risk of CC compared to standard or high-definition white light colonoscopy. However, limitations included unclear indication of colonoscopy in the studies (which included patients with screening and surveillance), and some heterogeneity in mean adenomas per patient. The evidence is insufficient to determine that the technology results in an improvement in the net health outcome.

For individuals who have an increased risk of CC who receive chromoendoscopy, the evidence includes systematic reviews and a recent RCT. Relevant outcomes are OS, DSS, test validity, and change in disease status. A Cochrane systematic review of trials comparing chromoendoscopy with standard colonoscopy in high-risk patients (but excluding those with inflammatory bowel disease [IBD]) found significantly higher rates of adenoma detection and rates of 3 or more adenomas with chromoendoscopy than with standard colonoscopy. The evidence for detecting larger polyps, defined as greater than 5 mm or greater than 10 mm, is less robust. While 1 study reported a significantly higher detection rate for polyps greater than 5 mm, no studies reported increased detection of polyps greater than 10 mm. A recent RCT and systematic review involving patients with Lynch syndrome also found equivocal results. Results from the RCT showed similar neoplasia detection rates with chromoendoscopy and conventional white-light colonoscopy, while the systematic review concluded that chromoendoscopy is associated with significantly improved detection of certain lesions; however, the odds of having an adenoma detected were not significantly different between the modalities. The evidence is insufficient to determine that the technology results in an improvement in the net health outcome.

For individuals who have IBD who receive chromoendoscopy, the evidence includes meta-analyses and a recent RCT. Relevant outcomes are OS, DSS, test validity, and change in disease status. Several meta-analyses found a statistically significant higher yield of chromoendoscopy over standard white-light colonoscopy for detecting dysplasia. The evidence supported improved polyp detection rates with chromoendoscopy; however, the studies had limitations such as lack of information regarding the timing of the screening modalities A recent RCT found increased detection of dysplasia with chromoendoscopy compared to white-light endoscopy, although the benefit was only observed in a a subgroup analysis in the second half of the study follow-up period. The evidence is insufficient to determine that the technology results in an improvement in the net health outcome.

Virtual Chromoendoscopy

For individuals who have an average risk of CC who receive virtual chromoendoscopy, the evidence includes several RCTs and systematic reviews. The relevant outcomes are OS, DSS, test validity, and change in disease status. The available RCTs have not found that virtual chromoendoscopy improves the detection of clinically important polyps compared with standard white-light colonoscopy. Moreover, there is a lack of studies on the impact of virtual chromoendoscopy on CC incidence or mortality rates compared with standard colonoscopy. The evidence is insufficient to determine that the technology results in an improvement in the net health outcome.

For individuals who have an increased risk of CC who receive virtual chromoendoscopy, the evidence includes RCTs. The relevant outcomes are OS, DSS, test validity, and change in disease status. The available RCTs have not found that virtual chromoendoscopy improves the detection of clinically important polyps compared with standard white-light colonoscopy. Moreover, there is a lack of studies on the impact of virtual chromoendoscopy on CC incidence or mortality rates compared with standard colonoscopy. The evidence is insufficient to determine that the technology results in an improvement in the net health outcome.

For individuals who have IBD who receive virtual chromoendoscopy, the evidence includes 2 meta-analyses and 2 RCTs. Relevant outcomes are OS, DSS, test validity, and change in disease status. One meta-analysis showed superiority of virtual chromoendoscopy over high-definition white light colonoscopy for dysplasia per biopsy, and ranked virtual chromoendoscopy as the best option for screening among the different modalities in comparison. The second meta-analysis found no difference between dye-based chromoendoscopy and virtual chromoendoscopy for dysplasia detection. One RCT found a significantly greater likelihood that virtual chromoendoscopy would correctly identify the extent of disease inflammation than standard colonoscopy but no significant difference in the likelihood of identifying disease activity. The other RCT found that there was no significant difference in the detection of neoplasia between high definition white light versus high-definition virtual chromoendoscopy in patients with long-standing IBD. There is a lack of studies assessing the impact of virtual chromoendoscopy on CC incidence and mortality rates compared with standard colonoscopy. The evidence is insufficient to determine that the technology results in an improvement in the net health outcome.

Practice Guidelines and Position Statements

American Society for Gastrointestinal Endoscopy and the American Gastroenterological Association

In 2021, the American Gastroenterological Association (AGA) published a clinical practice update on the surveillance and management of colorectal dysplasia in patients with inflammatory bowel disease (IBD). This was an expert review that underwent internal peer review by the AGA Clinical Practice Updates Committee and external peer review through standard procedures undertaken by the publishing journal (Gastroenterology). Table 1 summarizes relevant best practice statements.

Table 1. Best Practice Advice on Surveillance and Management of Dysplasia in Patients With Inflammatory Bowel Disease

Best Practice Statement

"Dye spray chromoendoscopy, performed by appropriately trained endoscopists, should be considered in all persons with colonic inflammatory bowel disease undergoing surveillance colonoscopy, particularly if a standard definition endoscope is used or if there is a history of dysplasia"

"Virtual chromoendoscopy is a suitable alternative to dye spray chromoendoscopy for dysplasia detection in persons with colonic inflammatory bowel disease when using high-definition endoscopy."

"Extensive nontargeted biopsies (roughly 4 adequately spaced biopsies every 10 cm) should be taken from flat colorectal mucosa in areas previously affected by colitis when white light endoscopy is used without dye spray chromoendoscopy or virtual chromoendoscopy. Additional biopsies should be taken from areas of prior dysplasia or poor mucosal visibility. Nontargeted biopsies are not routinely required if dye spraychromoendoscopy or virtual chromoendoscopy is performed using a high-definition endoscope, but should be considered if there is a history of dysplasia or primary sclerosing cholangitis."

"A finding of invisible dysplasia should prompt repeat examination by an experienced endoscopist using high-definition dye spraychromoendoscopy under optimized viewing conditions, with extensive nontargeted biopsies in the area of prior dysplasia if no lesion is seen. A finding of unresectable visible dysplasia or of invisible multifocal or high-grade dysplasia on histology should prompt colectomy. For visible lesions that can be resected or if histologic dysplasia is not confirmed on a high-quality dye spray chromoendoscopy examination, continued endoscopic surveillance at frequent intervals is appropriate.

"Targeted biopsies of representative or concerning pseudopolyps is appropriate during colonoscopy. Removal and sampling of all lesions is neither required nor practical. Surgery should be a last resort to manage colorectal cancer risk in the setting of severe pseudopolyposis. Dye spray chromoendoscopy should not be used to detect flat or subtle lesions within a field of pseudopolyps."

In 2015, the American Society for Gastrointestinal Endoscopy (ASGE) and the American Gastroenterological Association (AGA)published a SCENIC consensus statement on the surveillance and management of dysplasia in patients with IBD. This statement, developed by an international multidisciplinary group representing a variety of stakeholders, incorporated systematic reviews of the literature. Table 2 summarizes relevant recommendations.

Table 2. Recommendations on Surveillance and Management of Dysplasia in Patients with Inflammatory Bowel Disease

Recommendation

LOA

SOR

QOE

“When performing surveillance with white-light colonoscopy, high definition is recommended rather than standard definition.”

80%

Strong

Low

“When performing surveillance with standard-definition colonoscopy, chromoendoscopy is recommended rather than white-light colonoscopy.”

85%

Strong

Moderate

“When performing surveillance with high-definition colonoscopy, chromoendoscopy is suggested rather than white-light colonoscopy.”

84%

Conditional

Low

LOA: level of agreement; QOE: quality of evidence; SOR: strength of recommendation.

Panelists did not reach consensus on the use of chromoendoscopy in random biopsies of patients with IBD undergoing surveillance.

Commentaries in 2 gastroenterology journals questioned whether the SCENIC guidelines would be accepted as the standard of care in IBD surveillance. Both commentaries noted that the guidelines considered the outcome of the detection of dysplasia and not disease progression or survival. Moreover, the commentators noted the lack of longitudinal data on clinical outcomes in patients with dysplastic lesions detected using chromoendoscopy. Two other articles published in 2022 comment on how the approach to dysplasia surveillance in IBD has changed significantly since the publication of the SCENIC guidelines, and therefore, updates to the recommendations are warranted based on findings from recent meta-analyses and randomized trials (discussed in this review).

Then ASGE (2015) issued guidelines on endoscopy in the diagnosis and treatment of IBD, which made the following recommendations about chromoendoscopy: "Chromoendoscopy with pancolonic dye spraying and targeted biopsies is sufficient for surveillance in inflammatory bowel disease; consider 2 biopsies from each colon segment for histologic staging."

The ASGE (2015) also published a systematic review and meta-analysis assessing narrow-band imaging, i-SCAN, and Fujinon Intelligent Color Enhancement for predicting adenomatous polyp histology of small or diminutive colorectal polyps to determine whether they have met previously established criteria or thresholds to incorporate into clinical practice.

The ASGE assessment confirmed that:

"....The thresholds have been met for narrow-band imaging with endoscopists who are experts in using these advanced imaging technologies and when assessments are made with high confidence. The ASGE Technology Committee endorsed the use of NBI[narrow band imaging] for both the ‘diagnose-and-leave’ strategy for diminutive (≤5 mm) rectosigmoid hyperplastic polyps and the‘resect-and-discard’ strategy for diminutive (≤5 mm) adenomatous polyps."

The report addressed the “trepidation” of patients, endoscopists, and pathologists with the “diagnose-and-leave” strategy, indicating there are challenges for implementation for the use of these strategies in clinical practice.

U.S. Multi-Society Task Force on Colorectal Cancer

In 2020, the Multi-Society Task Force issued guidelines on the endoscopic removal of colorectal lesions. Regarding lesion assessment and description, the Task Force suggested "proficiency in the use of electronic- (e.g., NBI, i-SCAN, and Fuji Intelligent Chromoendoscopy, or blue light imaging) or dye (chromoendoscopy)-based image-enhanced endoscopy techniques to apply optical diagnosis classifications for colorectal lesion histology [conditional recommendation, moderate-quality evidence)." The Task Force also suggested "careful examination of the post-mucosectomy scar site using enhanced imaging, such as dye-based (chromoendoscopy) or electronic-based methods, as well as obtaining targeted biopsies of the site. Post-resection scar sites that show both normal macroscopic and microscopic (biopsy) findings have the highest predictive value for long-term eradication [conditional recommendation, moderate-quality evidence]."

The 2012 Multi-Society Task Force guidelines on colonoscopy surveillance after screening and polypectomy (consensus update) stated that chromoendoscopy and NBI might enable endoscopists to accurately determine if lesions are neoplastic and if there is a need to remove them and send specimens to pathology. The guidelines noted that these technologies currently do not have an impact on surveillance interval.

U.S. Preventive Services Task Force Recommendations

The U.S. Preventive Services Task Force (2021) recommendations on screening for colorectal cancer do not mention chromoendoscopy.

KEY WORDS:

Chromoendoscopy, Chromoscopy, Chromocolonoscopy. Virtual chromoendoscopy, FICE, i-scan, NBI

APPROVED BY GOVERNING BODIES:

In August 2014, the EPX-4440HD Digital Video Processor with Fujinon Intelligent Color Enhancement (FICE®) and Light Source (FujiFilm) was cleared for marketing by the U.S. Food and Drug Administration (FDA) through the 510(k) process (K140149). The FDA documents stated that FICE could be used to supplement white-light endoscopy but is not intended to replace histopathologic sampling as a means of diagnosis.

In June 2012, the i-SCAN™ (Pentax), used for virtual chromoendoscopy, was cleared for marketing by the FDA through the 510(k) process. This is a digital image enhancement technology and is part of the Pentax EPK-i5010 Video Processor. This digital image enhancement technology is part of the Pentax EPK-i5010 Video Processor. The i-SCAN™ has several modes that digitally enhance images in real-time during endoscopy. The FDA documents stated that i-SCAN™ is intended as an adjunct following white-light endoscopy but not intended to replace histopathologic analysis.

No dye or stain product has been specifically approved by the FDA for use in chromoendoscopy.

BENEFIT APPLICATION:

Coverage is subject to member’s specific benefits.  Group-specific policy will supersede this policy when applicable.

ITS: Home Policy provisions apply.

FEP:  Special benefit consideration may apply.  Refer to member’s benefit plan.  

CURRENT CODING: 

There is no specific coding for chromoendoscopy. The additional work of the chromoendoscopy would probably be reported with the unlisted CPT code 44799 (unlisted procedure, intestine) or 78299 (unlisted gastrointestinal procedure, diagnostic nuclear medicine).

REFERENCES:

  1. Abu Dayyeh BK, Thosani N, Konda V, et al. ASGE Technology Committee systematic review and meta-analysis assessing the ASGE PIVI thresholds for adopting real-time endoscopic assessment of the histology of diminutive colorectal polyps. Gastrointest Endosc. Mar 2015;81(3):502.e501-502.e16.
  2. Alexandersson B, Hamad Y, Andreasson A, et al. High-Definition Chromoendoscopy Superior to High-Definition White-Light Endoscopy in Surveillance of Inflammatory Bowel Diseases in a Randomized Trial. Clin Gastroenterol Hepatol. Aug 2020;18(9): 2101-2107.
  3. Antonelli G, Correale L, Spadaccini M, et al. Dye-based chromoendoscopy for the detection of colorectal neoplasia: meta-analysis of randomized controlled trials. Gastrointest Endosc. Sep 2022; 96(3): 411-422. 
  4. Bisschops R, Bessissow T, Joseph JA, et al. Chromoendoscopy versus narrow band imaging in UC: a prospectiverandomised controlled trial. Gut. Jun 2018; 67(6): 1087-1094.
  5. Brown SR, Baraza W, Din S, et al. Chromoscopy versus conventional endoscopy for the detection of polyps in the colon and rectum. Cochrane Database Syst Rev. Apr 07 2016;4(4):CD006439.
  6. Cassinotti A, Buffoli F, Fociani P, et al. Virtual Chromoendoscopy With FICE for the Classification of Polypoid and Nonpolypoid Raised Lesions in Ulcerative Colitis. J Clin Gastroenterol. Apr 2019; 53(4): 269-276.
  7. Chung SJ, Kim D, Song JH et al. Comparison of detection and miss rates of narrow band imaging, flexible spectral imaging chromoendoscopy and white light at screening colonoscopy: a randomized controlled back-to-back study. Gut May 2014; 63(5): 785-91.
  8. Davidson KW, Barry MJ, Mangione CM, et al. Screening for Colorectal Cancer: US Preventive Services Task Force Recommendation Statement. JAMA. May 18 2021; 325(19): 1965-1977.
  9. Desai M, Viswanathan L, Gupta N, et al. Impact of Electronic Chromoendoscopy on Adenoma Miss Rates During Colonoscopy: A Systematic Review and Meta-analysis. Dis Colon Rectum. Sep 2019; 62(9): 1124-1134.
  10. Feitosa F, Carlos A, Guilherme Nogueira J et al. Narrow-band imaging and chromoendoscopy for the detecion ofcolonicdysplasia in inflammatory bowel disease: a prospective and randomized study. Inflamm Bowel Dis 2011.
  11. Feuerstein JD, Rakowsky S, Sattler L, et al. Meta-analysis of dye-based chromoendoscopy compared with standard- and high-definition white-light endoscopy in patients with inflammatory bowel disease at increased risk of colon cancer. Gastrointest Endosc. Aug 2019; 90(2): 186-195.e1.
  12. Food and Drug Administration (FDA). 510(k) Summary: Pentax EPK-i5010 Video Processor. 2013. Available online at: www.accessdata.fda.gov/cdrh_docs/pdf12/K122470.pdf.
  13. Food and Drug Administration (FDA). Medical and Radiation Emitting Device Recalls. Class 2 Recall, EPX-4400 and EPX-4400HDVideo Processor. Available online at //www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfRes/resCollection_2.cfm?ID=96961&CREATE_DT=2011-02-09.
  14. Freire P, Figueiredo P, Cardoso R, et al. Surveillance in ulcerative colitis: is chromoendoscopy-guided endomicroscopy always better than conventual colonoscopy? A randomized trial. Inflamm Bowel Dis. Nov 2014; 20(11): 2038-2045.
  15. Gasia MF, Ghosh S, Panaccione R, et al. Targeted Biopsies Identify Larger Proportions of Patients With Colonic Neoplasia Undergoing High-Definition Colonoscopy, Dye Chromoendoscopy, or Electronic Virtual Chromoendoscopy. Clin Gastroenterol Hepatol. May 2016;14(5):704-712 e4.
  16. Gondal B, Haider H, Komaki Y, et al. Efficacy of various endoscopic modalities in detecting dysplasia in ulcerative colitis: Asystematic review and network meta-analysis. World J Gastrointest Endosc. May 16 2020; 12(5): 159-171.
  17. Gulati S, Dubois P, Carter B, et al. A Randomized Crossover Trial of Conventional vs Virtual Chromoendoscopy for ColitisSurveillance: Dysplasia Detection, Feasibility, and Patient Acceptability (CONVINCE). Inflamm Bowel Dis. May 04 2019;25(6): 1096-1106.
  18. Günther U, Kusch D, Heller F, et al. Surveillance colonoscopy in patients with inflammatory bowel disease: comparison ofrandom biopsy vs. targeted biopsy protocols. Int J Colorectal Dis. May 2011; 26(5): 667-72.
  19. Gupta S, Lieberman D, Anderson JC, et al. Recommendations for Follow-Up After Colonoscopy and Polypectomy: A Consensus Update by the US Multi-Society Task Force on Colorectal Cancer. Am J Gastroenterol. Mar 2020; 115(3): 415-434.
  20. Haanstra JF, Dekker E, Cats A, et al. Effect of chromoendoscopy in the proximal colon on colorectal neoplasia detection in Lynch syndrome: a multicenter randomized controlled trial. Gastrointest Endosc. Oct 2019; 90(4): 624-632.
  21. Har-Noy O, Yung DE, Koulaouzidis A, et al. Chromoendoscopy or white light endoscopy for neoplasia detection in Lynch syndrome, a meta-analysis. Dig Liver Dis. Nov 2019; 51(11): 1515-1521.
  22. Higgins PD. Miles to Go on the SCENIC Route: Should chromoendoscopy become the standard of care in IBD surveillance? Am J Gastroenterol. Jul 2015;110(7):1035-1037.
  23. Hlavaty T, Huorka M, Koller T, et al. Colorectal cancer screening in patients with ulcerative and Crohn's colitis with use ofcolonoscopy, chromoendoscopy and confocal endomicroscopy. Eur J Gastroenterol Hepatol. Aug 2011; 23(8): 680-9.
  24. Hurlstone DP, Cross SS, Slater R et al. Detecting diminutive colorectal lesions at colonoscopy: a randomized controlled trial of pan-colonic versus targeted chromoscopy. Gut Mar 2004; 53(3):376-80.
  25. Hurt C, Ramaraj R, Farr A, et al. Feasibility and economic assessment of chromocolonoscopy for detection of proximal serrated neoplasia within a population-based colorectal cancer screening programme (CONSCOP): an open-label,randomised controlled non-inferiority trial. Lancet Gastroenterol Hepatol. May 2019; 4(5): 364-375.
  26. Iacucci M, Kaplan GG, Panaccione R, et al. A Randomized Trial Comparing High Definition Colonoscopy Alone With HighDefinition Dye Spraying and Electronic Virtual Chromoendoscopy for Detection of Colonic Neoplastic Lesions During IBD Surveillance Colonoscopy. Am J Gastroenterol. Feb 2018; 113(2): 225-234.
  27. Iacucci M, Hassan C, Fort Gasia M, et al. Serrated adenoma prevalence in inflammatory bowel disease surveillance colonoscopy, and characteristics revealed by chromoendoscopy and virtual chromoendoscopy. Can J Gastroenterol Hepatol. Dec 2014; 28(11): 589-94.
  28. Ignjatovic A, East JE, Subramanian V, et al. Narrow band imaging for detection of dysplasia in colitis: a randomizedcontrolled trial. Am J Gastroenterol. Jun 2012; 107(6): 885-90.
  29. IOM (Institute of Medicine). 2011. Clinical Practice Guidelines We Can Trust. Washington, DC: The National Academies Press.
  30. Kaltenbach T, Anderson JC, Burke CA, et al. Endoscopic Removal of Colorectal Lesions-Recommendations by the US Multi-Society Task Force on Colorectal Cancer. Gastroenterology. Mar 2020; 158(4): 1095-1129.
  31. Kandiah K, Subramaniam S, Thayalasekaran S, et al. Multicentre randomised controlled trial on virtual chromoendoscopy in the detection of neoplasia during colitis surveillance high-definition colonoscopy (the VIRTUOSO trial). Gut. Sep 2021; 70(9): 1684-1690.
  32. Karolinska University Hospital. Chromoendoscopy for dysplasia detection in chronic inflammatory bowel disease (NCT01505842). Available online at: www.clinicaltrials.gov.
  33. Kiesslich R. SCENIC update 2021: Is chromoendoscopy still standard of care for inflammatory bowel disease surveillance?. Gastrointest Endosc. Jan 2022; 95(1): 38-41.
  34. Kiriyama S, Matsuda T, Nakajima T et al. Detectability of colon polyp using computed virtual chromoendoscopy with flexible spectral imaging color enhancement. Diagn Ther Endosc 2012; 2012:596303.
  35. Laine L, Kaltenbach T, Barkun A, et al. SCENIC international consensus statement on surveillance and management of dysplasia in inflammatory bowel disease. Gastroenterology. Mar 2015;148(3):639-651 e28.
  36. Leifeld L, Rogler G, Stallmach A, et al. White-Light or Narrow-Band Imaging Colonoscopy in Surveillance of UlcerativeColitis: A Prospective Multicenter Study. Clin Gastroenterol Hepatol. Oct 2015; 13(10): 1776-1781.e1.
  37. Lesne A, Rouquette O, Touzet S, et al. Adenoma detection with blue-water infusion colonoscopy: a randomized trial.Endoscopy. Aug 2017; 49(8): 765-775.
  38. Lieberman DA, Rex DK, Winawer SJ et al. Guidelines for colonoscopy surveillance after screening and polypectomy: a consensus update by the US Multi-Society Task Force on Colorectal Cancer. Gastroenterology Sep 2012; 143(3):844-57.
  39. Marion JF, Sands BE. The SCENIC consensus statement on surveillance and management of dysplasia in inflammatory bowel disease: praise and words of caution. Gastroenterology. Mar 2015;148(3):462-467.
  40. Marion JF, Waye JD, Israel Y, et al. Chromoendoscopy Is More Effective Than Standard Colonoscopy in Detecting Dysplasia During Long-term Surveillance of Patients With Colitis. Clin Gastroenterol Hepatol. May 2016;14(5):713-719.
  41. Mohammed N, Kant P, Abid F et al. OC-028 High definition white light endoscopy (HDWLE) versus high definition with chromoendoscopy (HDCE) in the detection of dysplasia in long standing ulcerative colitis: a randomised controlled trial.Gut 2015.
  42. Mooiweer E, van der Meulen-de Jong AE, Ponsioen CY, et al. Chromoendoscopy for surveillance in inflammatory bowel disease does not increase neoplasia detection compared with conventional colonoscopy with random biopsies: results from a large retrospective study. Am J Gastroenterol. Jul 2015;110(7):1014-1021.
  43. Murthy SK, Feuerstein JD, Nguyen GC, et al. AGA Clinical Practice Update on Endoscopic Surveillance and Management of Colorectal Dysplasia in Inflammatory Bowel Diseases: Expert Review. Gastroenterology. Sep 2021; 161(3): 1043-1051.e4.
  44. Neumann H, Vieth M, Gunther C et al. Virtual chromoendoscopy for prediction of severity and disease extent in patients with inflammatory bowel disease: a randomized controlled study. Inflamm Bowel Dis Aug 2013; 19(9):1935-42.
  45. Omata F, Ohde S, Deshpande GA, et al. Image-enhanced, chromo, and cap-assisted colonoscopy for improving adenoma/neoplasia detection rate: a systematic review and meta-analysis. Scand J Gastroenterol. Feb 2014; 49 (2): 222-237.
  46. Park SJ, Kim HS, Yang DH et al. High definition chromoendoscopy with water-jet versus high definition white lightendoscopy in the detection of dysplasia in long standing ulcerative colitis: a multicenter prospective randomized controlledstudy. Gastroenterology 2016;150:S1270.
  47. Pellisé M, López-Cerón M, Rodríguez de Miguel C, et al. Narrow-band imaging as an alternative to chromoendoscopy for the detection of dysplasia in long-standing inflammatory bowel disease: a prospective, randomized, crossover study.Gastrointest Endosc. Oct 2011; 74(4): 840-8.
  48. Pohl J, Schneider A, Vogell H et al. Pancolonic chromoendoscopy with indigo carmine versus standard colonoscopy for detection of neoplastic lesions: a randomized two-centre trial. Gut Apr 2011; 60(4):485-90.
  49. Rabinowitz LG, Kumta NA, Marion JF. Beyond the SCENIC route: updates in chromoendoscopy and dysplasia screening in patients with inflammatory bowel disease. Gastrointest Endosc. Jan 2022; 95(1): 30-37.
  50. Repici A, Wallace MB, East JE, et al. Efficacy of Per-oral Methylene Blue Formulation for Screening Colonoscopy.Gastroenterology. Jun 2019; 156(8): 2198-2207.e1.
  51. Resende RH, Ribeiro IB, de Moura DTH, et al. Surveillance in inflammatory bowel disease: is chromoendoscopy the onlyway to go? A systematic review and meta-analysis of randomized clinical trials. Endosc Int Open. May 2020; 8(5): E578-E590.
  52. Shergill AK, Lightdale JR, Bruining DH, et al. The role of endoscopy in inflammatory bowel disease. Gastrointest Endosc. May 2015;81(5):1101-1121 e1-13.
  53. Sponsored by Universitaire Ziekenhuizen Leuven (Belgium). Comparison between chromoendoscopy and virtual chromoendoscopy (NBI, I-scan, FICE) for detection of neoplasia in long standing ulcerative colitis (NCT01882205). Available online at: clinicaltrials.gov.
  54. Subramanian V, Mannath J, Ragunath K et al. Meta-analysis: the diagnostic yield of chromoendoscopy for detecting dysplasia in patients with colonic inflammatory bowel disease. Aliment Pharmacol Ther 2011; 33(3):304-12.
  55. U.S. Food & Drug Administration. 510(k) Premarket Notification (K140149). 2014; www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm?ID=K140149. 
  56. USPSTF, Bibbins-Domingo K, Grossman DC, et al. Screening for Colorectal Cancer: US Preventive Services Task Force Recommendation Statement. JAMA. Jun 21 2016;315(23):2564-2575.
  57. van den Broek FJ, Fockens P, van Eeden S, et al. Narrow-band imaging versus high-definition endoscopy for thediagnosis of neoplasia in ulcerative colitis. Endoscopy. Feb 2011; 43(2): 108-15.
  58. Vleugels JLA, Rutter MD, Ragunath K, et al. Chromoendoscopy versus autofluorescence imaging for neoplasia detectionin patients with longstanding ulcerative colitis (FIND-UC): an international, multicentre, randomised controlled trial. Lancet Gastroenterol Hepatol. May 2018; 3(5): 305-316.
  59. Wan J, Zhang Q, Liang SH, et al. Chromoendoscopy with targeted biopsies is superior to white-light endoscopy for the long-term follow-up detection of dysplasia in ulcerative colitis patients: a multicenter randomized-controlled trial. Gastroenterol Rep (Oxf). Jan 2021;9(1): 14-21.
  60. Watanabe K, Nishishita M, Shimamoto F, et al. 722 Comparison Between Newly-Developed Narrow Band Imaging andPanchromoendoscopy for Surveillance Colonoscopy in Patients With Longstanding Ulcerative Colitis: A Prospective Multicenter Randomized Controlled Trial, Navigator Study. Gastrointestinal Endoscopy 2016; 83: AB172.
  61. Wu L, Li P, Wu J et al. The diagnostic accuracy of chromoendoscopy for dysplasia in ulcerative colitis: meta-analysis of six randomized controlled trials. Colorectal Dis 2012; 14(4):416-20.
  62. Zhao S, Wang S, Pan P, et al. Magnitude, Risk Factors, and Factors Associated With Adenoma Miss Rate of Tandem Colonoscopy: A Systematic Review and Meta-analysis. Gastroenterology. May 2019; 156(6): 1661-1674.e11.

POLICY HISTORY:

Medical Policy Group, March, 2012 (4)

Medical Policy Administration Committee, March, 2012

Available for comment April 13 through May 28, 2012

Medical Policy Panel, March 2013

Medical Policy Group, April 2013 (3): 2013 Updates to Key Points and References; no change in policy statement

Medical Policy Panel, March 2014

Medical Policy Group, March 2014 (3):  2014 Updates to Key Points, Governing Bodies, & References; no change in policy statement

Medical Policy Panel, March 2015

Medical Policy Group, March 2015 (4): Updates to Key Points, Coding, and References. No change to policy statement.

Medical Policy Panel, November 2015

Medical Policy Group, November 2015 (4): Updates to Key Points and References; no change to policy statement.

Medical Policy Panel, November 2016

Medical Policy Group, January 2017 (4): Updates to Description, Key Points and References; no change to policy statement.

Medical Policy Panel, November 2017

Medical Policy Group, December 2017 (4):  Updates to Key Points and References, no change to policy statement.

Medical Policy Panel, December 2018

Medical Policy Group, December 2018 (4): Updates to Key Points. No change to policy statement.

Medical Policy Panel, November 2019

Medical Policy Group, November 2019 (5): Updates to Description, Key Points, Approved by Governing Bodies, and Practice Guidelines and Position Statements. No change to Policy Statement.

Medical Policy Panel, November 2020

Medical Policy Group, December 2020 (5): Updates to Description, Key Points, Practice Guidelines and Position Statements, and References. No change to Policy Statement.

Medical Policy Panel, November 2021

Medical Policy Group, November 2021 (5): Updates to Description, Key Points, Practice Guidelines, Governing Bodies, USPSTF and References. Policy statement updated to remove “not medically necessary,” no change to policy intent.

Medical Policy Panel, November 2022

Medical Policy Group, November 2022 (5): Updates to Description, Key Points, Practice Guidelines and Position Statements, and References. No change to Policy Statement.

Medical Policy Panel, November 2023

Medical Policy Group, November 2023 (11): Updates to Key Points, Benefit Application, and References. No change to Policy Statement.

                                                                                                                                    

This medical policy is not an authorization, certification, explanation of benefits, or a contract. Eligibility and benefits are determined on a case-by-case basis according to the terms of the member’s plan in effect as of the date services are rendered. All medical policies are based on (i) research of current medical literature and (ii) review of common medical practices in the treatment and diagnosis of disease as of the date hereof. Physicians and other providers are solely responsible for all aspects of medical care and treatment, including the type, quality, and levels of care and treatment.

This policy is intended to be used for adjudication of claims (including pre-admission certification, pre-determinations, and pre-procedure review) in Blue Cross and Blue Shield’s administration of plan contracts.

The plan does not approve or deny procedures, services, testing, or equipment for our members. Our decisions concern coverage only. The decision of whether or not to have a certain test, treatment or procedure is one made between the physician and his/her patient. The plan administers benefits based on the member’s contract and corporate medical policies. Physicians should always exercise their best medical judgment in providing the care they feel is most appropriate for their patients. Needed care should not be delayed or refused because of a coverage determination.

As a general rule, benefits are payable under health plans only in cases of medical necessity and only if services or supplies are not investigational, provided the customer group contracts have such coverage.

The following Association Technology Evaluation Criteria must be met for a service/supply to be considered for coverage:

1. The technology must have final approval from the appropriate government regulatory bodies;

2. The scientific evidence must permit conclusions concerning the effect of the technology on health outcomes;

3. The technology must improve the net health outcome;

4. The technology must be as beneficial as any established alternatives;

5. The improvement must be attainable outside the investigational setting.

Medical Necessity means that health care services (e.g., procedures, treatments, supplies, devices, equipment, facilities or drugs) that a physician, exercising prudent clinical judgment, would provide to a patient for the purpose of preventing, evaluating, diagnosing or treating an illness, injury or disease or its symptoms, and that are:

1. In accordance with generally accepted standards of medical practice; and

2. Clinically appropriate in terms of type, frequency, extent, site and duration and considered effective for the patient’s illness, injury or disease; and

3. Not primarily for the convenience of the patient, physician or other health care provider; and

4. Not more costly than an alternative service or sequence of services at least as likely to produce equivalent therapeutic or diagnostic results as to the diagnosis or treatment of that patient’s illness, injury or disease.